What will Crispr stock be worth in 2025?

What will Crispr stock be worth in 2025?

The weighted average target price per CRISPR Therapeutics share in Sep 2025 is: 105.70.

Is CRSP a buy right now?

CRISPR Therapeutics has received a consensus rating of Buy.

Is CRSP a buy or sell?

Zacks Rank Definition Annualized Return ---------- ---------- ----------------- 1 Strong Buy 25.25% 2 Buy 18.80% 3 Hold 10.34% 4 Sell 6.03%

Why Crispr stock is going down?

What happened. Shares of CRISPR Therapeutics (NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.8 Jan 2022

What is the best Crispr stock?

Company Market Cap ----------------------------------- ------------ CRISPR Therapeutics (NASDAQ:CRSP) $6.1 billion Editas Medicine (NASDAQ:EDIT) $1.9 billion Intellia Therapeutics (NASDAQ:NTLA) $8.9 billion Verve Therapeutics (NASDAQ:VERV) $1.9 billion

Why is CRSP stock dropping?

Shares of CRISPR Therapeutics (NASDAQ:CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.8 Jan 2022

Is CRSP overpriced?

The stock of CRISPR Therapeutics AG (NAS:CRSP, 30-year Financials) gives every indication of being significantly overvalued, according to GuruFocus Value calculation. At its current price of $131.88 per share and the market cap of $10 billion, CRISPR Therapeutics AG stock is estimated to be significantly overvalued.29 Apr 2021

Related Posts:

  1. What does CRISPR target?
  2. Is NASDAQ CM OTC?
  3. What are the 5 stages of editing?
  4. What is GUIDE Seq analysis?